{
    "nct_id": "NCT04735978",
    "official_title": "An Open-Label, Multicenter, Phase 1 Study of RP3 as a Single Agent and in Combination With PD-1 Blockade in Patients With Solid Tumors",
    "inclusion_criteria": "* Patients with advanced or metastatic non-neurological solid tumors, who have progressed on standard therapy or cannot tolerate standard therapy, or for whom there is no standard therapy preferred to enrollment in a clinical study\n* All patients must consent to provide archival tumor biopsy samples within 12 months, or a fresh tumor biopsy is needed. Patients must also consent to provide on treatment biopsies as per protocol\n* At least one measurable tumor ≥ 1 cm in longest diameter (or shortest diameter for lymph nodes)\n* At least one injectable tumor ≥ 1 cm in longest diameter or injectable tumors which in aggregate are ≥ 1 cm in longest diameter (or shortest diameter for lymph nodes\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n\nNote: Predefined inclusion criteria may apply for each additional expansion cohort.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with an oncolytic virus therapy\n* History of viral infections according to the protocol\n* Systemic infection requiring intravenous (IV) antibiotics\n* Active significant herpetic infections or prior complications of HSV-1 infection (e.g., herpetic keratitis or encephalitis)\n* Requires intermittent or chronic use of systemic antivirals\n\n  a. Hepatocellular carcinoma patients with a diagnosis of hepatitis B must be off antiviral therapy for at least 4 weeks prior to enrollment . Hepatocellular carcinoma patients with a history of or ongoing hepatitis C infection must have completed treatment for hepatitis C at least 1 month prior to study enrollment and hepatitis\n* History of interstitial lung disease\n* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis\n\nAdditional Exclusion Criteria for Patients Enrolled in Part 2 (Expansion Cohorts):\n\n* History of life-threatening toxicity related to prior immune treatment or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways\n* Treatment with botanical preparations within 2 weeks prior to treatment.\n* Active, known, or suspected autoimmune disease requiring systemic treatment.\n* History of interstitial lung disease.\n* Severe hypersensitivity to another monoclonal antibody.\n* Has received prior radiotherapy within 2 weeks of start of study treatment.\n* Has received a live vaccine within 28 days prior to the first dose of study treatment.\n* History of (non-infectious) pneumonitis that required steroids or has current pneumonitis.\n* History of myocarditis or congestive heart failure within 6 months of screening.\n* Has a serious or uncontrolled medical disorder.\n* Has a QT interval corrected for heart rate using Fridericia's formula (QTcF) > 480 msec, except for right bundle branch block.",
    "miscellaneous_criteria": ""
}